immune checkpoint inhibitors
Predicting response to checkpoint inhibitors and overcoming resistance in lung cancers
The role of PD-L1: is it accurate enough as a biomarker for immunotherapy response?
Exciting randomized trials for mesothelioma: checkpoint inhibitor monotherapies and vinorelbine
Lung cancer immunotherapy test standardization: the Blueprint PD-L1 IHC Assay Comparison Project
The role of immunotherapy in the radical treatment of NSCLC: where are we headed?
What does the 2-year follow-up tell us about the use of pembrolizumab for advanced bladder cancer?
Will immune checkpoint inhibitors become the new standard of care for urothelial cancer?